Digital Pathology Today™ is your podcast all about the world of digital pathology.  Each week, we talk with industry leaders, key academics, top pathologists and more to discover the past, present and future of digital pathology.  Join us every week for another look at Digital Pathology Today™.

Hosted by pathologist Dr. Joseph Anderson.

Current Episode

Season 3, Episode 14

Digital Pathology in the Cloud

This episode of Digital Pathology Today™ our guest is Alan Lorimer Co-Founder and CEO of Sciento.  

Moving digital pathology to the cloud.  We're talking about cloud computing the features and components of the cloud and how it differs from on premise computing. What are the barriers and overlooked considerations in moving your operations to the cloud? What is the truth about storage costs in 2024? Is it still a concern or have the gains been eaten away by the increasingly large amounts of data we continue to generate? 

How can cloud computing unlock exciting new applications at a lower cost for organizations?   And finally we discuss regulatory considerations for the cloud from the perspective of the FDA EU, GDPR and GCP in developing new drugs and diagnostics.

Alan Lorimer, started his professional journey as an electronics engineer at the BBC. Over his 40-year career, he's founded or led four successful businesses. Notably, he drove an IT hosting company to a successful exit in 2011. He then specialized in IT due diligence for around 60  European companies going through some kind of transaction, sharpening his analytical prowess. 

In 2016, Alan pivoted to digital pathology, creating the innovative QDPconnect with OracleBio, leading to the launch of Sciento Technology. Alan's journey from the BBC to cloud computing exemplifies his relentless drive for tech innovation and industry impact.

All opinions and views expressed on Digital Pathology Today™ are those of the individual expressing them.  No guests have paid nor been paid for their appearance on Digital Pathology Today™.   Digital Pathology Today™ does not endorse any specific products or technologies mentioned on the show.